- Home
- Clinical Care
- MASH, formerly NASH: the silent liver disease and what has changed
MASH, formerly NASH: the silent liver disease and what has changed
Liver health · Understanding MASH
GRAYMEDY EXPLAINER · Editorial review: October 17, 2026
A liver condition can advance without announcing itself through pain or obvious illness. That is the practical challenge behind MASH: people may feel well while inflammation and tissue injury are developing. The useful response is a conversation about metabolic health and liver scarring, rather than waiting for symptoms.
This guide starts with Pfizer’s educational article about NASH and updates its terminology and treatment context. The central message still matters: liver disease can occur in people who drink little or no alcohol. But older articles need to be read alongside newer clinical guidance and regulatory decisions.
From NASH to MASH: understanding the names
In June 2023, a multinational consensus introduced new names. MASLD means metabolic dysfunction-associated steatotic liver disease: liver fat together with at least one cardiometabolic risk factor. MASH, metabolic dysfunction-associated steatohepatitis, replaces the name NASH. Steatotic liver disease is the broader umbrella, which also includes other causes of liver fat.
The shift brings metabolic health into the definition. It also recognizes that alcohol and metabolic risk can coexist; a separate category, MetALD, describes an overlapping group. An honest alcohol history helps clinicians classify disease and plan care. The names are explained in AASLD’s nomenclature guide.
Fat, inflammation and scarring are different findings
Finding fat in the liver does not, by itself, establish MASH. MASH includes inflammation and injury to liver cells. Fibrosis means scar tissue; cirrhosis describes an advanced stage in which scarring has substantially altered the liver’s structure. MASH may occur with or without fibrosis.
These distinctions matter because the presence and severity of scarring help determine the next steps in care. A scan showing liver fat and a test suggesting advanced fibrosis answer different questions. Disease does not progress at one fixed speed in everyone. See the AASLD clinical practice guidance for the clinical framework.
Why feeling well can be misleading
MASLD often produces few or no symptoms. Some people report tiredness or discomfort in the upper right abdomen, but these are not specific enough to diagnose liver disease. Even advanced disease can remain unnoticed. Metabolic risk factors—including type 2 diabetes, insulin resistance, obesity and abnormal blood lipids—can be a more useful reason to discuss assessment than symptoms alone.
Genes and other factors also influence susceptibility. This is a health condition to assess, not a judgment about willpower. NIDDK explains the symptoms and risk factors.
The question to bring to an appointment: “Given my metabolic risk factors or liver scan, should we assess the likelihood of liver scarring?”
Assessment usually begins without a biopsy
A clinician reviews medical history, medicines, alcohol use and possible alternative causes of liver disease. Blood tests and imaging contribute different pieces of information. Scores such as FIB-4 use routine blood results and age to estimate the likelihood of advanced fibrosis; they are risk-assessment tools, not a stand-alone diagnosis.
When more information is needed, elastography measures liver stiffness, and a specialist may request other tests. Current pathways often use a blood-based assessment followed by a second test such as elastography or ELF. AASLD describes this staged approach.
A biopsy can directly establish steatohepatitis by examining tissue, but it is not recommended for every person with suspected MASLD. Clinicians reserve it for situations where the result would resolve uncertainty or guide management. A routine scan showing fat cannot alone demonstrate the microscopic injury of MASH. NIDDK’s diagnostic overview explains the roles of these tests.
Treatment has changed since the older NASH explainer
The statement that there are no approved medicines is outdated in the United States. On March 14, 2024, the FDA approved Rezdiffra (resmetirom) for adults with noncirrhotic NASH and moderate-to-advanced fibrosis, alongside diet and exercise. Its accelerated approval relied on changes in inflammation and scarring; confirmatory evidence is required to establish clinical benefit. Nausea, diarrhea, liver toxicity, gallbladder problems and drug interactions are among the considerations clinicians must review. Read the FDA’s resmetirom announcement.
On August 15, 2025, the FDA also approved Wegovy (semaglutide) injection for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with stages F2–F3. This indication likewise received accelerated approval. Biopsy improvements do not yet establish the full effect on outcomes such as transplantation or death; longer follow-up is intended to answer that question. Treatment has important contraindications and adverse effects and requires an individual prescribing assessment. See the FDA’s semaglutide announcement and ongoing accelerated-approval requirements.
These approvals concern defined adult populations. They do not make every case of liver fat eligible for drug treatment, and U.S. approval does not establish availability or authorization in another country.
Everyday care remains part of the plan
Nutrition, physical activity and management of related metabolic conditions remain important. For people with overweight or obesity, gradual, supported weight reduction can reduce liver fat; larger sustained losses may improve inflammation and fibrosis. Exercise can help even when weight does not fall. Crash dieting and malnutrition can worsen liver disease.
Goals should fit the individual’s health, abilities and disease stage. Discuss alcohol use and check supplements with a clinician: “natural” products can still injure the liver. NIDDK’s lifestyle and treatment overview was last reviewed in April 2021; its older statement on medicine approvals is superseded by the FDA decisions linked above.
A practical appointment checklist
- Ask whether your results show liver fat, suspected inflammation, scarring, or a combination.
- Ask which fibrosis assessment is appropriate and what its limitations are.
- Bring a list of medicines and supplements, and discuss alcohol openly.
- Agree on achievable activity and nutrition goals and a follow-up plan.
- If medicine is considered, ask about eligibility, expected benefit, risks, interactions and monitoring.
Sources, attribution and image credit
Originating source: Pfizer, “Exploring NASH – Nonalcoholic Fatty Liver Disease”. No individual author or publication date was displayed in the reviewed article; its references include access dates in 2018. Graymedy independently wrote and structured this explainer and checked updates against AASLD, NIDDK and FDA sources linked above. Pfizer’s patient quotation and source image have not been reproduced.
Photo: Nephron / Wikimedia Commons, CC BY-SA 3.0.
Editorial review: October 17, 2026. This educational explainer focuses on adult disease and verified U.S. treatment decisions; it is not a complete drug-label review or individualized medical advice. Regulatory status and clinical guidance can change.
Clinical Care
View more
A new US indication for Jemperli (dostarlimab-gxly) brings an organ-preserving approach into the rectal-cancer conversation. The FDA granted accelerated approval on October 19 for previously untreated stage II or III disease with dMMR or MSI-H tumors, confirmed by an authorized test. This is a small, biologically defined group: the agency estimates roughly 3% of locally advanced rectal cancers have these features. The approval does not extend to every rectal cancer. A different pathway, with follow-up still essential In the 154-patient AZUR-1 study, almost three-quarters had avoided surgery, radiotherapy and chemotherapy after a median follow-up exceeding two years. Longer observation is needed to establish how durable the benefit is and how often cancer returns. Dostarlimab can also trigger severe or fatal immune reactions against healthy tissues. Avoiding conventional treatment does not remove the need for specialist care. The practical shift is a more individual discussion of tumor testing, treatment goals and surveillance. Accelerated approval makes an option available while the sponsor continues collecting evidence of lasting clinical benefit. FDA approval and evidence
After the smoke clears, wildfire survivors may still need lung-health follow-up
Women express interest in trials—but few report receiving an invitation
Diet during antibiotics: a transplant study puts the hospital menu under scrutiny
A mobile clinic can remove the journey to a hospital. Whether it can also make treatment easier to sustain is a different question. A new trial led by Steven Shoptaw and Nabila El-Bassel puts both questions into view, with findings that deserve attention without a victory-lap headline. Published on 4 November in JAMA Psychiatry, HPTN 094 compared two ways of connecting people who inject drugs with HIV prevention and opioid-use-disorder services. The mobile-clinic group experienced fewer deaths over a year. Yet the intervention did not significantly improve the trial's main measures of medication use. Both findings matter. The comparison was more demanding than no care The study enrolled 409 adults without HIV in Houston, Los Angeles, New York City, Philadelphia and Washington, D.C. Participants had opioid use disorder, were not receiving medication for it when enrolled, and were willing to consider treatment. They were randomly assigned to one of two approaches. For 26 weeks, the intervention group received peer navigation plus integrated services through a mobile medical unit. These included oral HIV pre-exposure prophylaxis, known as PrEP, addiction medication and limited clinical and supportive services. The comparison group also received peer navigation, connecting people with existing community services. That active comparison is important. The trial tested the extra contribution of bringing services together on a vehicle when navigation was already available. It cannot be read as mobile clinics versus abandonment, or as a test of whether peer support has value. A striking result with a small event count Four deaths were confirmed among 203 people assigned to the mobile intervention, compared with 13 among 206 assigned to community-service navigation. The reported hazard ratio was 0.29, the basis for the widely publicised 71% relative reduction. Mortality was a secondary outcome, and the researchers say the finding needs replication. The absolute numbers make the result easier to judge. Seventeen deaths across the trial are a serious human loss, but a limited foundation for estimating exactly how large a benefit another programme would deliver. The result supports further investigation; it does not establish a guaranteed effect for every city or patient group. Why the main outcomes still matter At 26 weeks, verified PrEP use was 5.4% in the intervention group and 2.9% in the comparison group. Confirmed addiction-medication use was 14.8% and 10.7%, respectively. Neither difference was statistically significant. The findings therefore leave the original challenge of sustained medication engagement unresolved. It would be misleading to turn the survival result into evidence that the programme succeeded on all its objectives. Equally, a headline declaring the service ineffective would overlook a potentially important signal. Different outcomes answer different questions, and a careful assessment keeps them visible together. Shoptaw and El-Bassel are testing a service model The programme brings a practical research question into the street: what changes when care is available near people facing fragmented services, unstable housing or stigma? Shoptaw at UCLA and El-Bassel at Columbia co-chaired the trial. NIH's account describes accessibility as a central reason for studying this approach. The published protocol also describes planning around local HIV and overdose patterns and available services. A clinic's location is part of its intervention. For readers assessing a similar service, the useful questions concern where it stops, when it operates and whether people can return consistently. What should follow the headline Graymedy's interpretation is that the next step should examine both replication and delivery. A larger or independent evaluation could test the mortality signal. Detailed work on treatment entry, interruptions and return could help explain why medication use remained difficult to sustain. Local teams would also need to assess staffing, referral relationships and continuity after the mobile programme ends. Those are implementation questions raised by the findings, not benefits demonstrated by this trial. A vehicle can provide a place for care; the evidence still has to show which parts of the service change outcomes. For people seeking support, this research is a reason to ask about accessible HIV prevention and addiction services locally. It is not a reason to wait for a particular mobile programme. The study's most useful contribution is a sharper question: how can care reach people repeatedly enough to make a lasting difference? For commissioners, the distinction also affects what to measure next. Counting visits alone would miss whether people remain connected to care. A useful evaluation should specify its clinical outcomes in advance and report practical difficulties alongside improvements, so other communities can judge what is transferable. Sources: HPTN 094 trial, JAMA Psychiatry; HPTN results announcement; NIH, 4 November 2026; Published study protocol. Photo: NIH / study clinic; artwork: Shepard Fairey. Reviewed 5 November 2026. Independently written from public sources; no interview was conducted. General information, not individual medical advice.
How early is too early for a new aortic valve? PROGRESS tests the boundary
Starting CPAP: why a follow-up plan matters as much as the machine
Five-year PHERGain results sharpen the question of who may avoid chemotherapy
Leaving the ward is not the end of treatment Hospital discharge can feel like a milestone, but recovery often continues in a less predictable environment. At home, patients and families become responsible for medicines, appointments, wound checks, mobility and recognizing new symptoms. Instructions delivered during a busy final ward round may be difficult to remember, especially after illness, surgery or a long admission. A safer discharge process begins before the patient reaches the exit and follows through once ordinary life resumes. Why the transition is vulnerable Different clinicians may have changed treatment while a patient was hospitalized. A long-standing tablet might have been stopped, a dose adjusted or a temporary prescription added. The final medication list must reconcile these changes with what is already at home. Problems arise when lists conflict, pharmacy supplies are delayed or patients cannot distinguish a new medicine from an old one. Care teams should confirm not merely what has been prescribed but what the patient will actually take. Making instructions understandable A clear plan explains the reason for admission, what improved, what still needs attention and what recovery should look like. Rather than asking whether someone understands, clinicians can invite them to describe the plan in their own words. This teach-back approach exposes misunderstandings without treating questions as a failure. Written guidance in an appropriate language, accessible formatting and a named contact help patients revisit instructions after fatigue or stress has eased. The importance of the first follow-up For some patients, an early telephone or in-person check can uncover difficulties before they become urgent. A nurse, pharmacist or primary-care clinician may ask whether medicines were obtained, symptoms changed, transport is available and a specialist appointment has been booked. The ideal timing depends on the diagnosis and clinical risk; there is no universal seventy-two-hour rule for everyone. Nevertheless, the opening days at home are a practical opportunity to identify unmet needs. Warning signs must be specific Advice to seek help if symptoms worsen is often too vague. Patients benefit from examples that fit their condition and a clear distinction between routine questions and emergencies. After surgery, this may include concerning bleeding, increasing redness or fever; after a breathing-related admission, it may include worsening breathlessness. Severe chest pain, marked difficulty breathing, new confusion or symptoms suggestive of stroke require emergency assessment. Discharge paperwork cannot replace individualized clinical advice. Recovery includes more than medical tests Someone can be medically ready for discharge yet struggle with stairs, food, transportation or caregiving responsibilities. Financial pressure, limited digital access and low health literacy can make a technically correct care plan difficult to follow. Social workers, occupational therapists, community teams and family caregivers may all be relevant. Good discharge planning therefore assesses the patient's living circumstances and what support is realistically available, not just whether vital signs have stabilized. Connecting hospital and community teams A discharge summary should reach the next clinician promptly and explain key findings, medication changes, pending results and requested follow-up. Pending tests are particularly important: somebody must be responsible for reviewing them and informing the patient when action is needed. When hospital and community records do not communicate well, patients may have to repeat their history or resolve contradictory advice. Shared responsibility and explicit handovers reduce that burden. A practical definition of success The goal is not simply to shorten hospital stays or reduce readmission numbers. It is to make the move home safe, comprehensible and sustainable. Providers can learn from patient calls, medication discrepancies, missed appointments and reports of confusion. Patients should leave knowing what to do today, what to expect next and whom to contact if the plan fails. The best discharge is not a stack of instructions; it is a reliable continuation of care. What families can ask before leaving Before discharge, patients and caregivers can ask for one updated medication list, written warning signs and the contact number for problems arising outside office hours. They can clarify who is booking the next appointment and who will communicate any outstanding results. If equipment, dressing supplies or help moving around is required, arrangements should be confirmed rather than assumed. Families should also know which symptoms call for emergency services instead of a routine callback. These questions are not a substitute for professional judgment; they help translate a hospital plan into a realistic set of actions at home.
Pressure-injury prevention starts with a daily plan for the person
Sudden confusion needs urgent care, even when the patient is quiet
